FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm

The FDA’s rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.